Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Prodia Widyahusada TbkPRWDF 69 3-Year EBITDA Growth Rate is -7.00% as of Mar. 2026. GuruFocus rates PRWDF with a GF Score™ of 69/100. The stock has 2 warning signs investors should review. Among 168 Medical Diagnostics & Research companies, PT Prodia Widyahusada Tbk ranks worse than 72.62% on this metric.
During the past 12 months, PT Prodia Widyahusada Tbk's average EBITDA Per Share Growth Rate was 2.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -7.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -4.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 14.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of PT Prodia Widyahusada Tbk was 46.30% per year. The lowest was -17.20% per year. And the median was 20.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
PT Prodia Widyahusada Tbk 3-Year EBITDA Growth Rate Related Terms
PRWDF vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, PT Prodia Widyahusada Tbk's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Prodia Widyahusada Tbk 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PT Prodia Widyahusada Tbk's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where PT Prodia Widyahusada Tbk's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -7.00% mean?
PT Prodia Widyahusada Tbk (PRWDF) has a 3-Year EBITDA Growth Rate of -7.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PT Prodia Widyahusada Tbk and its competitors. According to the industry distribution chart, PT Prodia Widyahusada Tbk ranks #122 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 72.6%.
Is PT Prodia Widyahusada Tbk's 3-Year EBITDA Growth Rate too high?
PT Prodia Widyahusada Tbk's current 3-Year EBITDA Growth Rate is -7.00%. Based on the distribution chart, PT Prodia Widyahusada Tbk ranks #122 out of 168 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, PT Prodia Widyahusada Tbk has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does PT Prodia Widyahusada Tbk's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PT Prodia Widyahusada Tbk ranks #122 out of 168 companies for 3-Year EBITDA Growth Rate. This places PT Prodia Widyahusada Tbk in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 10.80, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PT Prodia Widyahusada Tbk and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Prodia Widyahusada Tbk's current 3-Year EBITDA Growth Rate is -7.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Prodia Widyahusada Tbk stock overvalued right now?
PT Prodia Widyahusada Tbk (PRWDF) has a current 3-Year EBITDA Growth Rate of -7.00%. The current 3-Year EBITDA Growth Rate is -7.00%. PT Prodia Widyahusada Tbk's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For PT Prodia Widyahusada Tbk (PRWDF), the current 3-Year EBITDA Growth Rate is -7.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT Prodia Widyahusada Tbk provides health care testing services. The company provides analytic and diagnostic services for the medical professionals. It is engaged in health laboratories by conducting business activities such as setting up clinics, health laboratories, management of hospitals, and health checkup services. Its operating segments are Central: Jakarta; Sumatera: Sumatera, Kepulauan Riau; Greater Jakarta: Jakarta, Bogor, Depok, Tangerang, Bekasi, Lampung, Pangkal Pinang; West Java; Central Java; East Java, Bali, Nusa Tenggara; Kalimantan Sulampua: Kalimantan, Sulawesi, Ambon, Papua.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRWDF has been successfully added to your 
